on EUROBIO-SCIENTIFIC (EPA:ALERS)
Eurobio Scientific Reports 9% Revenue Increase for 2025
Eurobio Scientific has announced a 9% rise in annual revenue, reaching €168 million for 2025. Proprietary product sales contributed significantly, surging by 20% and comprising 35% of total revenue. International markets generated 42% of the company's revenue, underlining successful global expansion.
The gross margin dipped slightly to 45.5%, from structural price pressures and operational changes in Germany. Operating income saw a decrease, standing at €10.8 million, affected by increased marketing and administrative expenses.
Net profit ascended to €4.9 million, a 22% increase over the previous year, while the financial position showed a negative net cash flow due to ongoing debt servicing.
Eurobio Scientific continues to focus on proprietary product development, enhancing its diagnostics and life sciences offerings, while navigating upcoming changes in key distribution partnerships.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROBIO-SCIENTIFIC news